CADL vs. BCAX
CADL (Candel Therapeutics, Inc.) and BCAX (Bicara Therapeutics Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, CADL returned 53.04% vs 81.65% for BCAX. At a 0.32 correlation, their price movements are largely independent.
Performance
CADL vs. BCAX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CADL achieves a 55.75% return, which is significantly higher than BCAX's 18.84% return.
CADL
- 1D
- 4.51%
- 1M
- 16.87%
- YTD
- 55.75%
- 6M
- 75.30%
- 1Y
- 53.04%
- 3Y*
- 79.17%
- 5Y*
- —
- 10Y*
- —
BCAX
- 1D
- 1.83%
- 1M
- -11.97%
- YTD
- 18.84%
- 6M
- 10.13%
- 1Y
- 81.65%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CADL vs. BCAX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
CADL Candel Therapeutics, Inc. | 55.75% | -34.91% | 23.82% |
BCAX Bicara Therapeutics Inc | 18.84% | -3.39% | -25.59% |
Correlation
The correlation between CADL and BCAX is 0.40, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.40 |
Correlation (All Time) Calculated using the full available price history since Sep 16, 2024 | 0.32 |
Fundamentals
CADL:
$548.78M
BCAX:
$1.21B
CADL:
-$0.97
BCAX:
-$2.80
CADL:
3.98
BCAX:
2.36
CADL:
$0.00
BCAX:
$0.00
CADL:
-$600.00K
BCAX:
$0.00
CADL:
-$71.64M
BCAX:
-$169.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CADL vs. BCAX — Risk / Return Rank
CADL
BCAX
CADL vs. BCAX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Candel Therapeutics, Inc. (CADL) and Bicara Therapeutics Inc (BCAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CADL | BCAX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.58 | ||
| Sortino ratioReturn per unit of downside risk | -0.50 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.23 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.44 | 2.67 | -1.23 |
| Martin ratioReturn relative to average drawdown | 2.54 | 6.34 | -3.81 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CADL | BCAX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.73 | 1.31 | -0.58 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.03 | -0.11 | +0.14 |
Drawdowns
CADL vs. BCAX - Drawdown Comparison
The maximum CADL drawdown since its inception was -94.33%, which is greater than BCAX's maximum drawdown of -67.82%. Use the drawdown chart below to compare losses from any high point for CADL and BCAX.
Loading charts...
Drawdown Indicators
| CADL | BCAX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.33% | -67.82% | -26.51% |
Max Drawdown (1Y)Largest decline over 1 year | -37.04% | -30.76% | -6.28% |
Max Drawdown (3Y)Largest decline over 3 years | -72.86% | — | — |
Current DrawdownCurrent decline from peak | -37.14% | -26.12% | -11.02% |
Average DrawdownAverage peak-to-trough decline | -62.79% | -40.09% | -22.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.98% | 12.92% | +8.06% |
Volatility
CADL vs. BCAX - Volatility Comparison
Candel Therapeutics, Inc. (CADL) has a higher volatility of 16.28% compared to Bicara Therapeutics Inc (BCAX) at 14.28%. This indicates that CADL's price experiences larger fluctuations and is considered to be riskier than BCAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CADL | BCAX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.28% | 14.28% | +2.00% |
Volatility (6M)Calculated over the trailing 6-month period | 53.92% | 35.37% | +18.55% |
Volatility (1Y)Calculated over the trailing 1-year period | 72.87% | 63.48% | +9.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 167.21% | 77.40% | +89.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 167.21% | 77.40% | +89.81% |
Dividends
CADL vs. BCAX - Dividend Comparison
Neither CADL nor BCAX has paid dividends to shareholders.
Financials
CADL vs. BCAX - Financials Comparison
This section allows you to compare key financial metrics between Candel Therapeutics, Inc. and Bicara Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CADL and BCAX have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CADL has higher volatility (16.28%) compared to BCAX (14.28%). In terms of maximum drawdown, CADL dropped -94.33% vs BCAX's -67.82%.
BCAX currently has the higher Sharpe Ratio (1.31 vs 0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CADL and BCAX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer